Given that silencing of a number of m6A regulators contributes to tumor proliferation and metastasis, upregulation of these molecules with the aid of specific agonists may present an effective option for m6A tumor-targeted therapy (e.g., certain ligands can act as activators of the METTL3-14-WTAP complex [274]). Here, METTL3 is linked to neoplasm.